Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 1 Nov 2013

Shorter D, Nielsen D A, Huang W, Harding M J, Hamon S C, Kosten T R

Abstract excerpt

Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production. We examined whether a functional variant of the ADRA1A gene (Cys to Arg at codon 347 in exon 2, Cys347Arg) may enhance treatment response through decreased stimulation of this α1A-adrenoceptor, since antagonists of this receptor show promise in reducing cocaine use. Sixty-nine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Cocaine-Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine beta-Hydroxylase

Share to Genotype

Share to Methadone

Share to Opioid-Related Disorders

Share to Polymorphism, Genetic

Share to Receptors, Adrenergic, alpha-1

Source

Open in PubMed Open full text

Identifiers

PMID: 23849431
DOI: 10.1016/j.euroneuro.2013.05.014
PMCID: PMC3818518

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.PMID 23849431Read ↗

Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.Semantic proximity Read ↗

ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.Semantic proximity Read ↗

Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant.Semantic proximity Read ↗

The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.Semantic proximity Read ↗

Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.Semantic proximity Read ↗

The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.Semantic proximity Read ↗

Pharmacogenetic Role of Dopamine Transporter (SLC6A3) Variation on Response to Disulfiram Treatment for Cocaine AddictionSemantic proximity Read ↗

A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment.Semantic proximity Read ↗

Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.Semantic proximity Read ↗

Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study.Semantic proximity Read ↗

Genetic and epigenetic analysis of the serotonin 2A receptor in the context of cocaine abuse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.